{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:33:41Z","timestamp":1792773221706,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.reprotox.2026.109379","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:44:09Z","timestamp":1791960249000},"page":"109379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2024 and 2025"],"prefix":"10.1016","volume":"146","author":[{"given":"Paul","family":"Barrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reprotox.2026.109379_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.reprotox.2024.108727","article-title":"Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2022 and 2023","volume":"130","author":"Barrow","year":"2024","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2026.109379_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.reprotox.2016.04.018","article-title":"Review of embryo-fetal developmental toxicity studies performed for recent FDA-approved pharmaceuticals","volume":"64","author":"Ishihara-Hattori","year":"2016","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2026.109379_bib3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.reprotox.2022.06.012","article-title":"Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2020 and 2021","volume":"112","author":"Barrow","year":"2022","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2026.109379_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.reprotox.2018.04.008","article-title":"Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2016 and 2017","volume":"80","author":"Barrow","year":"2018","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2026.109379_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.reprotox.2020.06.013","article-title":"Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2018 and 2019","volume":"99","author":"Barrow","year":"2021","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2026.109379_bib6","unstructured":"FDA, 2014, Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling [WWW Document]https:\/\/www.fda.gov\/drugs\/labeling-information-drug-products\/pregnancy-and-lactation-labeling-resources(accessed 2.5.26).."},{"key":"10.1016\/j.reprotox.2026.109379_bib7","unstructured":"FDAOncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations. Guidance for Industry [WWW Document]2019(URL)https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211810s000lbl.pdf."},{"key":"10.1016\/j.reprotox.2026.109379_bib8","unstructured":"ICH, 2020, S5(R3) Detection of toxicity to reproduction for human pharmaceuticals [WWW Document]https:\/\/database.ich.org\/sites\/default\/files\/S5-R3_Step4_Guideline_2020_0218_1.pdf(accessed 2.5.26).."},{"key":"10.1016\/j.reprotox.2026.109379_bib9","unstructured":"ICH, 2011, Harmonised tripartite guideline: preclinical safety evaluation of biotechnology-derived pharmaceuticals. S6(R1) [WWW Document]https:\/\/database.ich.org\/sites\/default\/files\/S6_R1_Guideline_0.pdf(accessed 7.31.26).."},{"key":"10.1016\/j.reprotox.2026.109379_bib10","unstructured":"ICH, 2010(URL)Guidance for Industry: S9 Nonclinical Evaluation for Anticancer Pharmaceuticals [WWW Document]https:\/\/database.ich.org\/sites\/default\/files\/S9_Guideline.pdf."},{"key":"10.1016\/j.reprotox.2026.109379_bib11","unstructured":"ICH, 2009, Guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals [WWW Document]https:\/\/database.ich.org\/sites\/default\/files\/M3_R2__Guideline.pdf."},{"key":"10.1016\/j.reprotox.2026.109379_bib12","unstructured":"FDAIntercenter Agreement Between the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research [WWW Document] FDA2018https:\/\/www.fda.gov\/combination-products\/jurisdictional-information\/intercenter-agreement-between-center-drug-evaluation-and-research-and-center-biologics-evaluation (accessed 7.31.26)."},{"key":"10.1016\/j.reprotox.2026.109379_bib13","unstructured":"CDER, 2026. Novel Drug Approvals for 2025 [WWW Document]. FDA. URL https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2025 (accessed 5.22.26)."},{"key":"10.1016\/j.reprotox.2026.109379_bib14","unstructured":"CDER, 2025. Novel Drug Approvals for 2024 [WWW Document]. FDA. URL https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2024 (accessed 5.22.26)."},{"key":"10.1016\/j.reprotox.2026.109379_bib15","series-title":"Radiation protection of pregnant women in nuclear medicine [WWW Document]","author":"International Atomic Energy Agency","year":"2017"},{"key":"10.1016\/j.reprotox.2026.109379_bib16","first-page":"1","article-title":"Nuclear imaging of a pregnant patient: should we perform nuclear medicine procedures during pregnancy?","volume":"21","author":"Bural","year":"2012","journal-title":"Mol. Imag. Radionucl. Ther."},{"key":"10.1016\/j.reprotox.2026.109379_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.reprotox.2026.109379_bib18","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.95.16.9448","article-title":"Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice","volume":"95","author":"Ma","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.reprotox.2026.109379_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/31269","article-title":"Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development","volume":"393","author":"Zou","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.reprotox.2026.109379_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.reprotox.2026.109176","article-title":"Reduced food consumption triggers abortion in antibiotic-treated pregnant rabbits: insights from a pair-feeding study","volume":"140","author":"Matsuoka","year":"2026","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2026.109379_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.rbmo.2012.02.012","article-title":"Implication of MEK1 and MEK2 in the establishment of the blood\u2013placenta barrier during placentogenesis in mouse","volume":"25","author":"Charron","year":"2012","journal-title":"Reprod. Biomed. Online Trophobl. Dev. Symp."},{"key":"10.1016\/j.reprotox.2026.109379_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151788","article-title":"FAK regulates trophoblast functions of invasion and proliferation through Rap1 pathway in early-onset preeclampsia","volume":"763","author":"Wang","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.reprotox.2026.109379_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00006254-199410000-00026","article-title":"Reproductive Toxicology of Alkylating Agents","volume":"49","author":"Glantz","year":"1994","journal-title":"Obstet. Gynecol. Surv."},{"key":"10.1016\/j.reprotox.2026.109379_bib24","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s10072-023-07292-9","article-title":"Symptoms and age of prodromal Alzheimer\u2019s disease in Down syndrome: a systematic review and meta-analysis","volume":"45","author":"Shimizu","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.reprotox.2026.109379_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0962279900000454","article-title":"Colony stimulating factor-1 (CSF-1) in pregnancy","volume":"1","author":"Daiter","year":"1992","journal-title":"Reprod. Med. Rev."},{"key":"10.1016\/j.reprotox.2026.109379_bib26","unstructured":"FDA, 2025. Turalio USPI [WWW Document]. URL https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211810s000lbl.pdf (accessed 2.11.26)."},{"key":"10.1016\/j.reprotox.2026.109379_bib27","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood-2015-03-633958","article-title":"A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development","volume":"125","author":"Ellery","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.reprotox.2026.109379_bib28","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood.V90.3.944","article-title":"Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice","volume":"90","author":"Huang","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.reprotox.2026.109379_bib29","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.3216","article-title":"A review of three new Anti-interleukin-5 Monoclonal antibody therapies for severe asthma","author":"Agumadu","year":"2018","journal-title":"Cureus 10 e3216"},{"key":"10.1016\/j.reprotox.2026.109379_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100262","article-title":"Immune checkpoint inhibitor administration during pregnancy: a case series","volume":"6","author":"Andrikopoulou","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.reprotox.2026.109379_bib31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/j.gastro.2011.10.040","article-title":"Deficiency of Claudin-18 Causes Paracellular H+ Leakage, Up-regulation of Interleukin-1\u03b2, and Atrophic Gastritis in Mice","volume":"142","author":"Hayashi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.reprotox.2026.109379_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40487-021-00179-9","article-title":"Efficacy and safety of platinum-based chemotherapy for ovarian cancer during pregnancy: a systematic review and meta-analysis","volume":"10","author":"Pei","year":"2021","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.reprotox.2026.109379_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/nat.2014.0490","article-title":"Considerations for Assessment of Reproductive and Developmental Toxicity of Oligonucleotide-Based Therapeutics","volume":"24","author":"Cavagnaro","year":"2014","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.reprotox.2026.109379_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1964935","article-title":"Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings","volume":"13","author":"Germovsek","year":"2021","journal-title":"mAbs"},{"issue":"n\/a","key":"10.1016\/j.reprotox.2026.109379_bib35","article-title":"Science-Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels","author":"Bowman","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.reprotox.2026.109379_bib36","unstructured":"FDA, 2014, Pregnancy and Lactation Labeling Final Rulehttps:\/\/www.fda.gov\/vaccines-blood-biologics\/biologics-rules\/pregnancy-and-lactation-labeling-final-rule."}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623826002224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623826002224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:34:51Z","timestamp":1792766091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623826002224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"alternative-id":["S0890623826002224"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2026.109379","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2024 and 2025","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2026.109379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109379"}}